1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Breast Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Breast Cancer Market, by Therapy Type
8.1.1. Targeted Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Hormonal Therapy (Endocrine Therapy)
8.1.2.1. Market Revenue and Forecast
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Immunotherapy
8.1.4.1. Market Revenue and Forecast
9.1. Breast Cancer Market, by Cancer Type/Molecular Subtype
9.1.1. Hormone Receptor-Positive (HR+)
9.1.1.1. Market Revenue and Forecast
9.1.2. HER2-Positive (HER2+)
9.1.2.1. Market Revenue and Forecast
9.1.3. Triple-Negative Breast Cancer (TNBC)
9.1.3.1. Market Revenue and Forecast
9.1.4. Ductal Carcinoma In Situ (DCIS)
9.1.4.1. Market Revenue and Forecast
10.1. Breast Cancer Market, by Disease Stage
10.1.1. Early-Stage Breast Cancer (Stage 0–II)
10.1.1.1. Market Revenue and Forecast
10.1.2. Locally Advanced Breast Cancer (Stage III)
10.1.2.1. Market Revenue and Forecast
10.1.3. Metastatic Breast Cancer (Stage IV)
10.1.3.1. Market Revenue and Forecast
11.1. Breast Cancer Market, by End-Use
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Oncology Clinics/Specialty Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Ambulatory Surgical Centers
11.1.3.1. Market Revenue and Forecast
11.1.4. Cancer Research Institutes
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.1.3. Market Revenue and Forecast, by Disease Stage
12.1.4. Market Revenue and Forecast, by End-Use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.1.5.3. Market Revenue and Forecast, by Disease Stage
12.1.5.4. Market Revenue and Forecast, by End-Use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.1.6.3. Market Revenue and Forecast, by Disease Stage
12.1.6.4. Market Revenue and Forecast, by End-Use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.2.3. Market Revenue and Forecast, by Disease Stage
12.2.4. Market Revenue and Forecast, by End-Use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.2.5.3. Market Revenue and Forecast, by Disease Stage
12.2.5.4. Market Revenue and Forecast, by End-Use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.2.6.3. Market Revenue and Forecast, by Disease Stage
12.2.6.4. Market Revenue and Forecast, by End-Use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.2.7.3. Market Revenue and Forecast, by Disease Stage
12.2.7.4. Market Revenue and Forecast, by End-Use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.2.8.3. Market Revenue and Forecast, by Disease Stage
12.2.8.4. Market Revenue and Forecast, by End-Use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.3.3. Market Revenue and Forecast, by Disease Stage
12.3.4. Market Revenue and Forecast, by End-Use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.3.5.3. Market Revenue and Forecast, by Disease Stage
12.3.5.4. Market Revenue and Forecast, by End-Use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.3.6.3. Market Revenue and Forecast, by Disease Stage
12.3.6.4. Market Revenue and Forecast, by End-Use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.3.7.3. Market Revenue and Forecast, by Disease Stage
12.3.7.4. Market Revenue and Forecast, by End-Use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.3.8.3. Market Revenue and Forecast, by Disease Stage
12.3.8.4. Market Revenue and Forecast, by End-Use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.4.3. Market Revenue and Forecast, by Disease Stage
12.4.4. Market Revenue and Forecast, by End-Use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.4.5.3. Market Revenue and Forecast, by Disease Stage
12.4.5.4. Market Revenue and Forecast, by End-Use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.4.6.3. Market Revenue and Forecast, by Disease Stage
12.4.6.4. Market Revenue and Forecast, by End-Use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.4.7.3. Market Revenue and Forecast, by Disease Stage
12.4.7.4. Market Revenue and Forecast, by End-Use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.4.8.3. Market Revenue and Forecast, by Disease Stage
12.4.8.4. Market Revenue and Forecast, by End-Use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.5.3. Market Revenue and Forecast, by Disease Stage
12.5.4. Market Revenue and Forecast, by End-Use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.5.5.3. Market Revenue and Forecast, by Disease Stage
12.5.5.4. Market Revenue and Forecast, by End-Use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Cancer Type/Molecular Subtype
12.5.6.3. Market Revenue and Forecast, by Disease Stage
12.5.6.4. Market Revenue and Forecast, by End-Use
13.1. Merck & Co
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol Myers Squiib
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Kyowa Kirin
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Eisai Co.Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Sanofi
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AstraZeneca
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Eli Lilly and Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Genentech
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
